V8 Peptides — Engineered Performance
Research Library
Semaglutide Purity Testing: HPLC, Mass and Content Math
SemaglutideGuide

Semaglutide Purity Testing: HPLC, Mass and Content Math

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What does "≥98% purity" mean for a semaglutide research vial? It is a chromatographic statement: the main peak made up at least 98% of the integrated detector signal in an HPLC run. It is not the fraction of the vial's mass that is semaglutide, because water, counterions and salts add mass without adding signal, and it assumes impurities respond to the detector like the main peak, which the relative response factor literature shows is often untrue. A complete quality check combines HPLC area percent, a mass-spectrometry identity check against the formula C187H291N45O59, and a content determination. This article gives the arithmetic and a lot-acceptance table. V8 Peptides publishes lot COAs for its 10 mg lyophilized semaglutide vial, for laboratory research use only.

Quality-control pages for a research peptide often list tests without showing how the numbers relate. A researcher who receives a vial needs to know which test answers which question, what a number can and cannot mean, and which discrepancies deserve a repeat. This article walks through five questions (identity, chromatographic purity, content, impurity assignment, and handling-induced change) with formula-only worked examples whose numbers are illustrations, not measurements of any lot. For the underlying concepts see understanding HPLC purity, HPLC versus mass spectrometry and how to read a COA. For laboratory research use only.

What the V8 listing and COA state

The product page describes a 10 mg lyophilized powder in a sealed clear glass vial, purity ≥98% by HPLC, molecular formula C187H291N45O59, with the sequence or identity reported on the certificate of analysis where published, and a batch-specific COA available on the COA page. The documentation list on the page names compound identity and sequence, measured purity (HPLC %), identity confirmation, batch or lot number, analytical test date, and supplied form and storage. Use that list as the checklist to compare against the paper in hand.

COA fieldQuestion it answersCannot answer
Compound identityIs this the named molecule?Whether a minor isomer is present
HPLC purity (%)How much of the detector signal is the main peak?How much of the vial mass is peptide
Identity confirmationDoes measured mass match the formula?Folding, activity, or modifications of equal mass
Lot number and test dateWhich material and how old is the test?Current condition after storage
Supplied form and storageHow should it be kept?Stability after reconstitution

Identity: formula-to-mass arithmetic

From C187H291N45O59 the calculated average mass is about 4113.6 Da and the monoisotopic mass about 4111.1 Da (atomic weights: C 12.011, H 1.008, N 14.007, O 15.999; monoisotopic: C 12.0000, H 1.007825, N 14.003074, O 15.994915). A measured neutral mass is compared with the calculated value as an error: error (ppm) = (measured − calculated) ÷ calculated × 10⁶. For an illustrative measured monoisotopic value of 4111.14, the error is (4111.14 − 4111.115) ÷ 4111.115 × 10⁶ ≈ 6 ppm. Acceptable error depends on the instrument; a deviation of one dalton or more points to a different compound or a modification such as deamidation (+0.984 Da) or oxidation (+15.995 Da), not to calibration drift.

In electrospray, the spectrum shows multiply charged ions with m/z = (M + z × 1.00728) ÷ z, for example about 1029.4 for z = 4 and 823.7 for z = 5 on the average-mass scale. Computing the series for z = 3 to 7 gives a reference table to hold beside the spectrum.

Chromatographic purity and why impurities do not weigh the same

HPLC purity by area percent is area of main peak ÷ total area of all integrated peaks × 100. Illustration: a main peak of 9,800 area units and impurity peaks totaling 200 units gives 98.0%. The calculation assumes every species gives the same detector response per unit mass, and a paper on relative response factors points out that impurities in peptides arising from insertion, truncation, deamidation, isomerization and oxidation may not respond equally, so assuming a factor of 1 can overestimate or underestimate impurity levels (reference 1). If an impurity has RRF 1.5, a measured area of 150 corresponds to a true amount equivalent to 150 ÷ 1.5 = 100 area units of main-peak equivalent. Changing the integration or detector wavelength can change the percentage, so the method line on a COA (column, gradient, wavelength) matters as much as the number. Peak purity at 98% in one method does not guarantee the same in another, which is why orthogonal methods exist.

IllustrationMain peak areaImpurity areaArea percent
Clean run9,80020098.0%
Same impurity, RRF 1.5 applied9,800133 (200 ÷ 1.5)98.7%
Same impurity, RRF 0.5 applied9,800400 (200 ÷ 0.5)96.1%

The numbers are illustrations of a formula. They show that the same chromatogram can yield different percentages depending on assumptions, and why a ≥98% specification is best read with the method description.

Content: purity is not the same as mass fraction

A lyophilized peptide contains counterions, residual water and sometimes salts, so peptide content (net peptide, by weight) is below the HPLC purity. Illustration: a 10 mg vial with 85% net peptide content and 98% chromatographic purity holds about 10 × 0.85 = 8.5 mg of peptide-related material, of which about 98% by signal is the main species, or roughly 8.3 mg. A protocol specified by mass of the compound should account for this if the concentration matters, and the COA should be checked for whether a content value is given. Where it is not, quantification by amino-acid analysis, quantitative NMR or a calibrated HPLC standard is the way to obtain one; the choice is a laboratory decision. Using nominal vial mass for a stock calculation (C = m ÷ V) is the usual practice and gives a nominal concentration. The reconstitution calculator performs that arithmetic.

Impurities: where they come from and how they are discussed

Long synthetic peptides can carry process-related impurities (deletions, insertions, incomplete deprotection) and product-related ones from degradation. A perspective on generic peptide drugs describes how regulatory guidance asks sponsors to identify and characterize process- and product-related impurities that differ from the reference product and recommends orthogonal methods for immunogenicity assessment (reference 2). That is a pharmaceutical regulatory context and is cited here only to show how seriously impurity characterization is exposed; it does not describe or set any requirement for research materials.

For semaglutide specifically, a 2025 LC-HRMS study followed solution-state degradation at 25 °C and 40 °C across pH values, buffers and molarities, identified thirteen impurities with fragment assignments, reported that six formed under all conditions, and concluded that pH was a key factor (reference 3). Because solution conditions differ from a dry vial, the paper is a map of possible degradants and not a forecast. Degradation pathways and stress-testing strategies in general are reviewed in the forced-degradation literature (reference 4), which covers elevated temperature, freeze-thaw, mechanical stress, oxidation and light.

A lot-acceptance table

CheckPass condition (suggested)If it fails
Label versus COACompound name, lot number and formula agreeContact the supplier before opening
Physical appearanceIntact seal; white to off-white cake or powderRecord and photograph
Mass errorWithin the instrument's stated accuracy of the calculated valueRepeat; check calibration; consider adducts
HPLC area percentConsistent with the COA, using the same methodCompare method parameters before concluding
Unexplained peaksAssigned by mass shift or documented as unknownRepeat with fresh preparation to exclude prep artefacts
SolubilityClear solution in the chosen diluentRecord haze or particles; do not use for quantitative work
Record keepingCOA, chromatogram, spectrum and lot filed togetherReconstruct before any experiment

The pass conditions are suggestions for a laboratory's own procedure, not a standard. Choose limits before looking at the data, and apply the same limits to every lot.

Storage and handling effects on the numbers

A COA describes the lot at the time of testing. Afterward the material is influenced by storage. The product page states 2–8 °C, or −20 °C for long-term holding, with protection from heat, moisture and light. Allow a sealed vial to reach room temperature before opening to avoid condensation, record each opening, and divide a reconstituted stock into single-use portions. Methionine and aspartyl or asparaginyl residues are common sites of oxidation and deamidation in peptides generally, and the early chemistry of succinimide-linked reactions at asparaginyl and aspartyl residues is long established (reference 5). To confirm that a stock has not changed, repeat the same HPLC method at pre-set times and compare main-peak area percent and absolute area; a fall in absolute area without new peaks suggests adsorption or precipitation instead of degradation. See semaglutide storage and stability, reconstitution and handling and the lot-level semaglutide purity testing page.

For sourcing context see where to buy semaglutide, and the shop for the full catalog. Everything here is for laboratory research use only.

Frequently asked questions

What does ≥98% HPLC purity mean?

That the main peak was at least 98% of the integrated detector signal in the stated method. It is not the same as the percentage of the vial mass that is peptide.

Why can the same chromatogram give different purity values?

Impurities may respond to the detector differently from the main peak. Applying relative response factors, or changing wavelength or integration, shifts the percentage.

What mass should semaglutide show?

From C187H291N45O59: about 4113.6 Da average or 4111.1 Da monoisotopic, observed as a series of multiply charged ions in electrospray.

How do I express mass error?

error (ppm) = (measured − calculated) ÷ calculated × 10⁶. Differences near one dalton suggest a different compound or modification, not calibration drift.

What is peptide content?

The weight fraction of the lyophilized solid that is peptide, excluding water, counterions and salts. It is lower than HPLC purity and is not always reported.

What did the LC-HRMS degradation paper find?

Thirteen impurities under solution-state thermal stress, six formed under all tested conditions, with pH as a key factor. It does not describe a refrigerated dry vial.

What should a lot-acceptance procedure include?

Label-versus-COA agreement, appearance, mass error, HPLC area percent with the same method, assignment of unexplained peaks, solubility and record keeping.

How should the vial be stored?

The product page states 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light.

Where is the lot COA?

On the COA page, where a certificate has been published for the lot.

Is this article about use outside the laboratory?

No. It explains quality-control arithmetic and published analytical work. Semaglutide is supplied for laboratory research use only.

Related reading: Semaglutide Research Overview: GLP-1 Mechanisms and FAQ, Semaglutide Research Peptide Storage and Stability Guide, Semaglutide vs Tirzepatide vs Retatrutide: Receptor Panel.

References

  1. Kumar Kuril A. The Critical Need for Implementing RRF in the Accurate Assessment of Impurities in Peptide Therapeutics. Anal Chem. 2025;97(24):12480-12485. doi:10.1021/acs.analchem.5c02149
  2. De Groot AS, Mattei A, Gabriel B, Calderini J, Roberts BJ, Lelias S, et al. Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches. Pharm Res. 2025;42(5):805-818. doi:10.1007/s11095-025-03843-1
  3. Malgave A, Akbar S, Joseph A, Dande Aishwarya, Peraman R, Malayandi R. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery. Eur J Pharm Biopharm. 2025;214:114780. doi:10.1016/j.ejpb.2025.114780
  4. Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
  5. Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-94. PMID: 3805008
  6. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. doi:10.1021/acs.jmedchem.5b00726

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.